Stryker has signed a definitive merger agreement to purchase US-based medical technology firm Entellus Medical for about $662m.

Entellus was founded in 2006 and develops minimally invasive products for the treatment of ear, nose and throat (ENT) disorders.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Stryker expects that Entellus’ XprESS Multi-Sinus Dilation System and LATERA Absorbable Nasal Implant will be complementary to its ENT portfolio under the Instruments business.

Stryker MedSurg and Neurotechnology group president Timothy Scannell said: “Entellus is a leader in the ENT segment and offers a comprehensive portfolio of products that enable physicians to conveniently and comfortably perform a broad range of ENT procedures.”

The acquisition is subject to approvals and additional customary closing conditions, and is expected to aid in delivering cost-effective solutions for patients.

“Stryker purchased French company Vexim for an aggregated equity value on a fully diluted basis of around €183m ($215.7m).”

Entellus Medical CEO Robert White said: “The combination of Stryker’s established commitment to making healthcare better and Entellus’ innovative products within the ENT segment will continue to provide our customers the tools they need for cost-effective solutions.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In October, Stryker purchased French company Vexim for an aggregated equity value on a fully diluted basis of around €183m ($215.7m), corresponding to the approximate €162m ($190.9m) enterprise value.

Vexim develops and commercialises vertebral compression fracture (VCF) solutions such as the SpineJack mechanical expandable VCF implant designed to reduce and stabilise the fracture.

The firm’s product portfolio is said to be complementary to Stryker Instruments division’s Interventional Spine (IVS) business, which includes products for vertebral augmentation, vertebroplasty, and radiofrequency ablation procedures.